Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

By Carella Angelo   Lerma Enrica  

Annals of Hematology, Vol. 86, Iss. 10, 2007-10 ,pp. : 749-752

Springer Publishing Company

Access to resources Recommend Favorite

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

By Galanopoulos A.  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 281-282

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia

By Gutierrez-Aguirre Cesar Homero   Garcia-Rodriguez Fernando   Ortiz-Galvez Victor Manuel   Cantu-Rodriguez Olga Graciela   Salazar-Riojas Rosario   Martinez-Gonzalez Odra Lizzette   Gonzalez-Llano Oscar   Jaime-Pérez Jose Carlos   Ortiz-Lopez Rocio   Flores-Jimenez Juan Antonio   Alatorre-Ricardo Julio   Mancias-Guerra Consuelo   Gomez-Almaguer David  

Hematology, Vol. 18, Iss. 4, 2013-07 ,pp. : 224-229

Maney Publishing

Access to resources Recommend Favorite

Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance

By Chahardouli Bahram   Zaker Farhad   Mousavi Seied Asadollah   Kazemi Ahmad   Ostadali Mohammadreza   Nadali Fatemeh   Rostami Shahrbano   Alimoghaddam Kamran   Ghavamzade Ardeshir  

Hematology, Vol. 18, Iss. 3, 2013-05 ,pp. : 158-162

Maney Publishing

Access to resources Recommend Favorite